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atent Foramen Ovale Closure
or Migraine Prevention
he Subject Is Still Open*
avid W. Dodick, MD
hoenix, Arizona
igraine is a common, disabling, largely inherited neuro-
ogical disorder with a prevalence of 8% to 13% in the
opulation of the Western hemisphere (1,2). The prevailing
ypothesis regarding the pathogenesis of migraine is an
nherited excitability of certain brain networks that, when
riggered by particular endogenous or exogenous factors,
eads to a cascade of events that result in head pain, in
ddition to a multitude of other symptoms, including a
eightened sensitivity to movement and ambient light,
oise, and odor; nausea; emesis; cognitive impairment;
ertigo; depression; and lethargy (3). In approximately one-
hird of sufferers, an aura—consisting of reversible neurological
ymptoms such as visual illusions, unilateral paresthesias, and
xpressive/receptive language dysfunction—will precede or
ccur during some attacks. In addition, approximately 2% of
he population experiences a more disabling form of mi-
raine, known as chronic migraine, which is characterized
y headache on more than 15 days/month (4).
See page 282
Case-control, meta-analytic, and population-based stud-
es over the past decade have suggested that patent foramen
vale (PFO) is more common in migraineurs with aura and
hat migraine aura is more common in patients with PFO
5,6). The combination of migraine aura and right-to-left
hunt (RLS) has also been shown to be a strong and
ndependent predictor for persistent migraine (7). Retro-
pective and prospective studies examining the effect of
FO closure (largely to prevent recurrent presumed para-
oxical embolus) on migraine suggest a benefit to PFO
losure, but the grade of evidence from these studies is low
5). However, although suffering from significant limita-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona. Dr.
odick is the Principle Neurology Investigator for a patent foramen ovale closurea
tudy sponsored by St. Jude (study closed); he has also served as consultant for
oherex.ions, a single randomized sham-controlled study in the
nited Kingdom failed to meet its primary and secondary
nd points and suggested no benefit with regard to migraine
utcomes in patients who underwent PFO closure (8).
lthough the mechanism for a potential causal relationship
etween PFO and migraine is not clear, recent evidence
uggests that microembolization resulting in brief episodes
f cerebral hypoxia/ischemia can trigger cortical spreading
epression, a phenomena that is felt to be the underlying
echanism of migraine aura (9).
In this issue of JACC: Cardiovascular Interventions,
igatelli et al. (10) prospectively evaluated the effect of
rimary PFO transcatheter closure (n  40) with either the
mplatzer (AGA Medical Corp., Golden Valley, Minne-
ota) or Premere Closure device (St. Jude Medical, St. Paul,
innesota) versus medical therapy (n  46) on migraine
isability in subjects with anatomic and functional charac-
eristics predisposing to paradoxical embolism without pre-
ious cerebral ischemia. These characteristics included cur-
ain pattern RLS on transcranial Doppler and
ransesophageal echocardiography, refractory and disabling
igraine (Migraine Disability Assessment Scale grade 3 or
), PFO, RLS at rest, atrial septal aneurysm, an acquired or
nherited coagulopathy, and presence of Eustachian valve.
igraine disability was measured at months 6 and 12, and
esidual shunt was evaluated with contrast transesophageal
chocardiography (months 1, 6, and 12) and transcranial
oppler (month 1). Subjects were also asked whether they
xperienced a reduction in migraine headache and aura of
00%, 50%, 25%, or 0%.
They reported, after a mean follow-up period of 29
onths, complete closure in 95%—a significant reduction
n migraine disability compared with those who were
edically managed—and elimination of aura in all patients.
ike other studies, patients with and without aura seemed
o benefit from closure (27 of 32 [84%] aura subjects and 6
f 8 [75%] non-aura subjects had 50% or 100% reduction,
espectively, in migraine headaches). Two patients had a
ersistent small shunt, and 2 subjects developed early
ost-procedural atrial fibrillation restored to sinus rhythm
ith antiarrhythmic medication. The authors concluded
hat the results of their study suggest that patients with
natomic and functional characteristics highly predictive of
aradoxical embolism respond very favorably to transcath-
ter PFO closure with significant symptomatic improve-
ent or even cure and that these characteristics might
dentify migraine subjects most likely to respond to PFO
losure. They also speculate that the complete abolition of
ura suggest that aura itself might be related to certain
natomic and functional characteristics of the right atrium.
The study is novel in the selection of patients with
unctional and anatomical characteristics that increase the
isk of paradoxical embolism and important in that it
ttempts to identify a subgroup of migraine sufferers most
l
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289ikely to benefit from this procedure. The importance of
dentifying a patient-responsive subgroup cannot be over-
mphasized, if and when PFO closure is demonstrated to be
ffective for migraine prevention in a well-controlled study.
iven the prevalence of migraine in the population, it is
ritical that only those patients that are highly likely to
espond be subjected to an invasive cardiac procedure with
potential for serious adverse events. The study also benefits
rom the appropriate inclusion of an independent neurolo-
ist to make the diagnosis of migraine with the criteria of
nternational Classification of Headache Disorders, the
areful and long-term follow-up of subjects in the study, the
election of an appropriate device based on the anatomy and
imensions of the PFO, and the absence of a history of
aradoxical embolism (and presumed cerebral ischemia).
The authors appropriately outline some limitations of the
tudy, including a small sample size from a single center that
as not randomized or compared with a control group.
nfortunately, these limitations might be deal-breakers and
eriously limit the ability to interpret the results of this
tudy. The absence of a sham-control is clearly a serious
imitation, whereas the lack of randomization essentially
liminates any potential for the medically managed group to
erve as a “quasi-control,” because the 2 populations were
ery different. Indeed, the inclusion criteria seem to have
een applied only to the group undergoing closure and not
o the group who were medically managed. The group
articipants selected for PFO closure were significantly
ore likely to have aura, be disabled, have large shunts, and
ossess the functional and anatomical characteristics that
ncrease the risk of paradoxical embolism. The ability to
nterpret the results is also hampered, because accurate
aseline and follow-up frequency of migraine attacks, aura,
nd medication consumption with daily diaries were not
sed, as with most studies in this space. Moreover, the
efinition of medical refractoriness was not given, the use
nd duration of antiplatelet medications in either group was
ot addressed, and the concomitant use of prophylactic
edications in the PFO closure group was not noted.
The authors conclude that, before consideration for
linical therapy, future large-scale, multicenter, randomized
valuations are needed for further confirmation of their
reliminary findings. If PFO is a trigger for attacks in
ome patients and microembolism-induced cortical
preading depression—as suggested by recent preliminary
xperimental work—is the underlying mechanism, then the sigh-risk characteristics used in this study to select patients
or closure might indeed represent a closure-responsive
ubgroup. Unfortunately, although efforts have been made
o complete large-scale, multicenter randomized controlled
rials in the U.S., only 1 of 3 studies has remained open,
argely due to enrollment proceeding at a glacial pace.
oreover, it is unlikely that the design of these trials will
dentify a subgroup likely to respond to PFO closure.
lthough this study doesn’t get us closer to an answer, it
eeps the subject open and might guide the selection of
ubjects for future clinical trials.
eprint requests and correspondence: Dr. David W. Dodick,
epartment of Neurology, Mayo Clinic Arizona, 5777 East Mayo
oulevard, Phoenix, Arizona 85255. E-mail: Dodick.david@
ayo.edu.
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